Medical Device Toxicological Risk Assessment Guide

Introduction: Why Toxicological Risk Assessment Is Critical in 2026

In today’s highly regulated global healthcare landscape, toxicological risk assessment (TRA) for medical devices has become a cornerstone of patient safety, regulatory compliance, and product approval strategies. With evolving regulations such as EU MDR 2017/745, updated FDA biocompatibility guidance, and continuous revisions in ISO 10993 standards, manufacturers must adopt a risk-based, science-driven approach to evaluate chemical safety.

A primary concern in modern development is the presence of extractables and leachables (E&L) chemical substances that can migrate from device materials into the human body. Without robust assessment, these substances may pose cytotoxic, genotoxic, or systemic risks.

What is Toxicological Risk Assessment (TRA)?

Toxicological Risk Assessment (TRA) is a structured scientific process used to evaluate the potential health risks posed by chemical constituents in medical devices under intended conditions of use.

It integrates toxicology, chemistry, and exposure science to ensure that chemical exposure remains within acceptable safety thresholds, such as:

• Tolerable Intake (TI) 
• Threshold of Toxicological Concern (TTC) 
• Permitted Daily Exposure (PDE) 

Core Components of Toxicological Risk Assessment

1. Hazard Identification

• Identification of chemical constituents from materials 
• Use of analytical chemistry data & toxicological databases 
• Screening against carcinogenic, mutagenic, and reprotoxic (CMR) substances 

2. Exposure Assessment

• Evaluation of patient exposure scenarios 
• Consideration of: 
  • Device type (implant, external, short-term) 
  • Contact duration (acute, sub-chronic, chronic) 
  • Route of exposure (dermal, systemic, blood-contacting) 

3. Dose-Response Assessment

• Establishes relationship between dose and adverse effects
• Uses NOAEL, LOAEL, BMD models 

4. Risk Characterization

• Integration of hazard + exposure 
• Determines if risk is: 
  • Acceptable 
  • Requires mitigation 
  • Need further testing 

Key Standards Governing TRA

Extractables & Leachables (E&L): A Critical Focus Area

Extractables are compounds released under aggressive lab conditions, while leachables are substances released during actual device use.

Trending 2025–2026 Update:

• Increased regulatory emphasis on AET (Analytical Evaluation Threshold) 
• Integration of computational toxicology & QSAR modeling
• Adoption of non-animal testing approaches (NAMs) 

Advanced Testing & Evaluation Services

Maven Regulatory Solutions delivers end-to-end toxicological and biocompatibility services aligned with global regulatory expectations.

Comprehensive Testing Capabilities

Integrated Risk Management Approach

A robust TRA is not standalone it integrates with:

• Biological Evaluation Plan (BEP) 
• Biological Evaluation Report (BER) 
• Toxicological Risk Assessment Report (TRAR) 

Workflow Overview

Latest Regulatory Trends & Innovations (2026)

• EU MDR scrutiny on CMR substances & endocrine disruptors 
• FDA push for extractables/leachables justification using AET 
• Increased adoption of: 
  • In silico toxicology (QSAR models)
  • Read-across approaches 
  • AI-driven toxicological predictions 
• Focus on sustainability & green chemistry in materials

Why Choose Maven Regulatory Solutions?

1. Global Regulatory Expertise

Specialized in medical device toxicology, regulatory compliance, and risk assessment across US, EU, and global markets.

2. End-to-End TRA Services

From chemical characterization to regulatory submission support, ensuring seamless compliance.

3. Scientific Excellence

Multidisciplinary team including:

• Toxicologists 
• Regulatory experts 
• Biomedical scientists 

4. Compliance-Driven Approach

Aligned with:

• ISO 10993 series 
• ISO 14971 
• FDA & EU MDR requirements 

Conclusion

Toxicological Risk Assessment is no longer optional it is a regulatory necessity and competitive advantage. With increasing scrutiny on chemical safety, extractables & leachables, and biocompatibility, manufacturers must adopt a proactive, science-based approach.

Partnering with Maven Regulatory Solutions ensures your medical devices are:

• Safe for patients 
• Compliant with global standards 
• Ready for faster market approvals 

FAQs 

1. What is toxicological risk assessment for medical devices?

It is a scientific evaluation of chemical risks associated with device materials, ensuring exposure levels are within safe limits.

2. Why are extractables and leachables important?

They can migrate into the body and potentially cause toxicity, irritation, or long-term health risks.

3. What is ISO 10993-17?

A key standard that defines allowable limits for chemical substances in medical devices using TRA.

4. What is AET in E&L studies?

Analytical Evaluation Threshold (AET) determines the reporting threshold for chemical compounds during testing.

5. How does TRA support regulatory submissions?

It provides scientific justification of safety, essential for FDA, EU MDR, and global approvals.